FastIVF - Rapid IVF Assistance Pharmaceuticals Portal - Page 2

Future Biosimilars: Upcoming Patent Expirations and Market Entry

Future Biosimilars: Upcoming Patent Expirations and Market Entry

Upcoming patent expirations for top biologics like Keytruda and Humira will unleash a wave of biosimilars, slashing drug costs by up to 35%. Learn how these complex alternatives work, why adoption is slow in the U.S., and what it means for patients and healthcare spending.

FDA Inspection of Generic Manufacturing Facilities: What to Expect in 2026

FDA Inspection of Generic Manufacturing Facilities: What to Expect in 2026

Understand what happens during an FDA inspection of generic drug manufacturing facilities, including the six systems reviewed, common findings, how to respond to a Form FDA 483, and how the PreCheck program can help you prepare. Learn what inspectors really look for and how to avoid costly compliance failures.

Bioequivalence Testing for Generic Drugs: What It Proves

Bioequivalence Testing for Generic Drugs: What It Proves

Bioequivalence testing proves that generic drugs deliver the same amount of active ingredient at the same rate as brand-name drugs, ensuring they work just as well. It's the science behind why generics save billions without sacrificing effectiveness.